| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management dinner symposium and the Women in Chest Medicine Annual Luncheon.
"CHEST is a powerful platform for United Therapeutics and the pulmonary hypertension community to connect, share new developments, and elevate patient care," said Andrew Nelsen, PharmD, VP of Global Medical Affairs. "We're excited to sponsor the ‘PHinding Pulmonary Hypertension' symposium and showcase rapid-fire presentations, including real-world data on earlier inhaled treprostinil use and its impact on hospitalization rates, plus new insights from the PHINDER study to refine screening for PH-ILD."
Posted In: UTHR
